Status:
COMPLETED
Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Sanofi
Conditions:
Hyperglycemia
Diabetes
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit ...
Detailed Description
Critical illness causes an impairment of insulin secretion and insulin action, resulting in hyperglycemia even in normal individuals and a worsening of the hyperglycemia in patients with diabetes. Nor...
Eligibility Criteria
Inclusion
- Fasting glucose \> 100 mg/dl
- Patients on surgical services or in intensive care units receiving intravenous insulin
Exclusion
- Inability to obtain informed consent from patient or next-of-kin
- Allergy to insulin
- Participation in another research study
- Patients for whom there are "do-not-resuscitate" orders
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00338104
Start Date
July 1 2004
End Date
May 1 2005
Last Update
April 6 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611